Schonfeld Strategic Advisors LLC Buys New Stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Schonfeld Strategic Advisors LLC acquired a new position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,709,615 shares of the biopharmaceutical company's stock, valued at approximately $1,744,000. Schonfeld Strategic Advisors LLC owned approximately 0.82% of Sangamo Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Northern Trust Corp increased its stake in shares of Sangamo Therapeutics by 4.5% during the 4th quarter. Northern Trust Corp now owns 398,289 shares of the biopharmaceutical company's stock worth $406,000 after purchasing an additional 17,049 shares in the last quarter. Boothbay Fund Management LLC purchased a new position in shares of Sangamo Therapeutics during the 4th quarter worth approximately $548,000. EAM Investors LLC purchased a new position in shares of Sangamo Therapeutics during the 4th quarter worth approximately $256,000. Barclays PLC increased its stake in shares of Sangamo Therapeutics by 6,324,700.0% during the 4th quarter. Barclays PLC now owns 63,248 shares of the biopharmaceutical company's stock worth $65,000 after purchasing an additional 63,247 shares in the last quarter. Finally, ExodusPoint Capital Management LP purchased a new position in shares of Sangamo Therapeutics during the 4th quarter worth approximately $42,000. 56.93% of the stock is owned by hedge funds and other institutional investors.

Sangamo Therapeutics Stock Down 2.8%

Shares of NASDAQ SGMO traded down $0.02 during trading on Friday, hitting $0.70. 2,887,567 shares of the company traded hands, compared to its average volume of 8,638,178. Sangamo Therapeutics, Inc. has a 1 year low of $0.30 and a 1 year high of $3.18. The company has a 50-day moving average price of $0.78 and a 200-day moving average price of $1.36. The firm has a market capitalization of $160.44 million, a P/E ratio of -0.93 and a beta of 1.46.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The business had revenue of $7.55 million for the quarter, compared to analyst estimates of $11.70 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. Research analysts predict that Sangamo Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on SGMO. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $2.00 target price on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a research note on Monday, April 7th. Finally, Truist Financial lowered their target price on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a research note on Thursday, January 23rd. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, Sangamo Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $5.17.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.